Timely, reliable monitoring is vital when trying to accurately assess a newborn’s oxygenation status at birth and when screening for congenital heart defects. Committed to improving care for this fragile patient population, Masimo has designed sensors and monitoring solutions specifically for newborns that provide clinicians with pertinent physiological data quickly and efficiently – without sacrificing accuracy.
Masimo’s breakthrough Signal Extraction Technology® (SET®) overcomes the limitations of conventional pulse oximetry with the ability to measure through motion and low perfusion. Two separate studies found that Masimo SET® pulse oximeters detected approximately 10 times more true events than other “Next Generation” pulse oximeters studied.1,2
Masimo SET® had 3% missed true alarms and 5% false alarms versus 43% and 28%, respectively, using competitor technology.3
Results shown are calculated by combining sensitivity and specificity outcomes of machine-generated and volunteer-generated motion.
In another study comparing the ability of three pulse oximetry technologies to detect hypoxic events, Masimo SET® pulse oximetry demonstrated the highest sensitivity and specificity during induced conditions of motion and low perfusion.3
Newborn Neonatal SpO2 sensors automatically configure Masimo SET® pulse oximeters for the fastest response time and maximum sensitivity settings, allowing clinicians to focus on patient care during newborn resuscitation.
Masimo SET® was the first pulse oximetry technology to receive FDA 510(k) clearance in the labeling to screen newborn patients for critical congenital heart disease (CCHD).5
To date, there have been five published CCHD screening studies, representing a total of 241,239 infants, that used exclusively Masimo SET® pulse oximeters and sensors6-10, two of which (59,876 subjects) were the basis for the CCHD workgroup recommendation for CCHD screening protocols.8,9,11 These studies, all using Masimo SET®, concluded that pulse oximetry, in conjunction with clinical assessment, improved screening sensitivity compared to routine physical exam alone.6-10
Eve application is available on the Rad-97™ and Radical-7® Pulse CO-Oximeters®
Eve combines Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry with step-by-step instructions to assist clinicians in screening for CCHD. Eve simplifies the CCHD screening process, per an established protocol,7 by providing visual instructions, animations, an automatic synchronisation algorithm, and a detailed, easy-to-interpret display of screening results. In addition, screening data from Eve can be automatically sent to electronic medical records, helping simplify workflows and reduce reporting errors.
Multisite Y-I reusable sensors with soft foam wraps – which have been used in multiple prominent CCHD screening studies6-10 - enable quick, comfortable application and removal, without disturbing the patient.
RD SET™ Neo single-patient-use, wrap-around style sensors feature a flat, lightweight cable that lies comfortably on the patient’s hand or foot.
Hay WW. J of Perinatol, 2002;22:360-36.
Barker SJ. Anesth Analg. 2002;95(4):967-72.
Shah N. et al. J Clin Anesth. 2012 Aug;24(5):385-91.
American Academy of Pediatrics (AAP). (2016). Textbook of Neonatal Resuscitation, 7th Ed.
Masimo 510(k) Summary - K120657
de-Wahl Granelli A et al. Acta Paediatr. 2007 Oct;96(10):1455-9.
Meberg A et al. Pediatr. 2008 Jun;152(6):761-5.
de-Wahl Granelli A et al. BMJ. 2009 Jan 8;338:a3037.
Ewer AK et al. Lancet. 2011 Aug 27;378(9793):785-94.
Zhao QM et al. Lancet. 2014 Aug 30;384(9945):747-54.
Kemper AR et al. Pediatrics. 2011 Nov;128(5):e1259-67.
Eve has obtained CE Marking. Not available in the U.S. or Canada. Rad-97 NIBP is not licensed for sale in Canada.
For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.
© 2019 Masimo. All Rights Reserved.